CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 26 enrolled
Drug / intervention
Doxycycline +1 moredrug
Likely dose
Doxycycline 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04167085
NCT04167085Phase 4Completed
CompareCT.gov

NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL Trial

University of California, Los Angeles·interventional·Posted Nov 18, 2019·Updated Jul 20, 2022

In Brief

A Phase 4 clinical trial evaluating Doxycycline and Placebo for Epistaxis. Completed, enrolled 26 participants across 1 site.

Detailed Summary

The purpose of this research study is to determine whether Doxycycline can be used to control nosebleeds (epistaxis) for patients with Hereditary Hemorrhagic Telangiectasia (HHT). Patients with HHT will be randomized to one of 2 study arms: Doxycycline or Placebo for a period of 2 months followed by a 1-month washout period before switching treatments for a further 2 months period. Observation and evaluation will continue for a period of one month after treatment is completed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpistaxis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedNov 18, 2019
Enrollment StartDec 18, 2017
Primary CompletionJun 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 6.6 years ago

Interventions

Doxycyclinedrug

Doxycycline, 100 mg twice a day for 2 months

Placeboother

Matching placebo, twice a day for 2 months